Overweight on ANN

My view: Ansell (ASX: ANN) is a quality, mid-risk company suited for a long-term investment. It operates within a stable and expanding TAM, supported by rising global safety and healthcare demand. With its leadership in PPE, differentiated product portfolio, and ongoing margin improvement, Ansell is well positioned to gain sustained exposure to the industry’s structural tailwinds and deliver steady earnings growth.

Company Overview

Ansell is a global leader in personal protective equipment (PPE), providing hand and body protection solutions (B2B). It operates through 2 main segments: Healthcare (52%), which manufactures surgical, examination, and cleanroom gloves for hospitals, labs, and life-science firms); and Industrial (48%), which produces mechanical, chemical, and specialty protective solutions for workers in manufacturing, mining, and logistics industries.

Industry Overview

The broader PPE industry is forecasted to grow at roughly 7-8% CAGR from 2025-2033, reaching ~USD $160 billion by 2033, driven by stronger workplace safety regulation, elevated healthcare demand, and rising safety standards in emerging markets (APAC & MEA); India projected to grow at a 10.4% CAGR.

Investment Theses

1. Premium specialist, sticky revenue base, and industry leadership within a fragmented PPE market: The global PPE market is highly fragmented, with the top five players holding only ~30–35% market share. Within this environment, Ansell has established a defensible niche as a premium B2B specialist in hand and body protection, commanding roughly 20% global market share in both surgical and mechanical gloves and ranking #1 or #2 across its key verticals. Unlike low-cost Asian manufacturers that compete primarily on price and volume, Ansell differentiates itself through quality, reliability, and innovation. Its leading brands (Hyflex, TouchNTuff, and Microflex) command roughly a 15% price premium in mechanical gloves, with customers showing strong loyalty and willingness to pay, providing durable revenue stickiness. Supported by global distribution partners like Grainger, this brand strength and unique value preposition underpin a durable competitive moat.

2. Structural tailwinds + strategic expansion: Ansell is well-placed to capture increased structural demand in PPE, driven by tightening workplace-safety regulation, rising healthcare and hygiene standards, and accelerating industrialisation in emerging markets. Ansell is positioned to capture the structural tailwinds in global PPE demand through both organic and inorganic expansion. Ansell’s organic growth strategy leverages these tailwinds through increased penetration in under-served regions, new product innovation, and the cross-selling of its premium brands. Ansell acquired Kimberly-Clark’s PPE division (KBU) in 2024. Ansell has fully integrated KBU ahead of schedule and increased guidance for FY27 net pre-tax cost synergies target from $10m to $15m. This acquisition also widens its moat by adding higher margin cleanroom and laboratory PPE, diversifying away from basic single‐use gloves with slimmer margins.

3. Margin improvement & financial strength post-pandemic: Following pandemic-era supply disruptions and demand volatility, Ansell has undertaken a structural reset of its operations through its Accelerated Productivity Investment Program (APIP), launched in July 2023 to streamline manufacturing, improve supply-chain efficiency, and unify enterprise systems. The program has already delivered ~US$47 million (on track to save $50m in FY26) in annualised savings and completed key phases of manufacturing consolidation, including the relocation of certain production from China to Sri Lanka and warehouse upgrades across the US, UK, and Mexico. This is reflected in a reversal of its share price trajectory, beginning in 2023, when the program was launched. APIP has supported gross profit margin uplift from 34.1% in FY22 to 41.1% in FY25.

Investment Risks to Consider

A. Input cost and supply-chain risk: volatility in raw-material prices (nitrile, latex, energy), freight disruptions, and trade/tariff risks (i.e., US import tariffs) can pressure margins.

B. Competitive price pressure: Competition from low-cost Asian manufacturers that compete primarily on price and volume could compress margin and/or market share, especially in commoditised gloves.

C. Execution risk: Historically, Ansell has made a total of 11 acquisitions, with the biggest one being the KBU. While early results have been positive, integration complexity and potential delays in achieving targeted cost synergies present ongoing execution risk.

D. FX risk: With operations spanning over 100 countries and revenue denominated in multiple currencies (USD, EUR, MYR), Ansell’s earnings are exposed to transaction volatility from FX movements.